- Home
- PROK vs DHY Comparison
PROK vs DHY Comparison
Compare PROK & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- DHY
- Stock Information
- Founded
- PROK 2015
- DHY 1998
- Country
- PROK United States
- DHY United States
- Employees
- PROK N/A
- DHY N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- DHY Finance/Investors Services
- Sector
- PROK Health Care
- DHY Finance
- Exchange
- PROK Nasdaq
- DHY Nasdaq
- Market Cap
- PROK 237.4M
- DHY 221.5M
- IPO Year
- PROK N/A
- DHY N/A
- Fundamental
- Price
- PROK $1.54
- DHY $2.15
- Analyst Decision
- PROK Buy
- DHY
- Analyst Count
- PROK 5
- DHY 0
- Target Price
- PROK $4.50
- DHY N/A
- AVG Volume (30 Days)
- PROK 410.1K
- DHY 569.1K
- Earning Date
- PROK 11-12-2024
- DHY 01-01-0001
- Dividend Yield
- PROK N/A
- DHY 9.10%
- EPS Growth
- PROK N/A
- DHY N/A
- EPS
- PROK N/A
- DHY N/A
- Revenue
- PROK N/A
- DHY N/A
- Revenue This Year
- PROK N/A
- DHY N/A
- Revenue Next Year
- PROK N/A
- DHY N/A
- P/E Ratio
- PROK N/A
- DHY N/A
- Revenue Growth
- PROK N/A
- DHY N/A
- 52 Week Low
- PROK $1.18
- DHY $1.77
- 52 Week High
- PROK $4.44
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- PROK 37.52
- DHY 38.12
- Support Level
- PROK $1.70
- DHY $2.20
- Resistance Level
- PROK $2.03
- DHY $2.17
- Average True Range (ATR)
- PROK 0.21
- DHY 0.03
- MACD
- PROK -0.04
- DHY -0.00
- Stochastic Oscillator
- PROK 0.74
- DHY 10.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company with the objective to seek high current income and capital appreciation as a secondary objective.